According to the National Institutes of Health, CME or Continuing Medical Education, consists of educational activities which serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession.
The IMF and Medscape bring you a series of videos for myeloma practitioners to earn such CME credits. This series includes:
This supplement to JADPRO has been developed by members of the International Myeloma Foundation (IMF) Nurse Leadership Board.
“Advances in the diagnosis and management of multiple myeloma (MM) and other plasma cell disorders such as AL amyloidosis and Waldenström macroglobulinemia (WM) continue to evolve rapidly. Over the past several years, there have been significant gains in understanding disease biology, leading to improvements in diagnostic techniques, a shift towards targeted therapies, and a potential transition away from traditional chemotherapeutic agents as the standard of care.”
This CE-certified supplement provides FREE Credits/Contact Hours for Nurses and other Advanced Practitioners; it is jointly provided by the IMF, the Annenberg Center for Health Sciences at Eisenhower, and JADPRO.
In this CME series, IMF Chief Scientific Officer and Chairman of the Board Dr. Brian G.M. Durie is joined by leading myeloma practitioner Dr. Thomas Martin (University of California San Francisco—San Francisco) to discuss BCMA-directed therapies in multiple myeloma. Complete all sections of these activities to earn CME credit.
Upon completion of this activity, participants should be better able to:
- Discuss treatment regimens for patients with newly diagnosed or relapsed multiple myeloma including appropriate symptom management and patient education
- Identify healthcare disparities faced by patients with multiple myeloma who are part of minority groups and strategies to overcome these
- Describe strategies to support the patient’s input in therapeutic decisions
In this CME series, IMF Chief Medical Officer Joseph Mikhael (Professor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen) at City of Hope Cancer Center – Phoenix) provides education for primary care providers and hematologists/oncologists on the signs and symptoms of multiple myeloma (MM) so they can remove barriers to earlier diagnosis and improve treatment in the African - American community.
In this CME series, IMF Chairman of the Board Dr. Brian G.M. Durie is joined by leading multiple myeloma practitioners to discuss frontline therapy, approaches to relapse care management, novel strategies for heavily pretreated myeloma patients, side effect management, clinical trials, and more. Complete all sections of these activities to earn CME credit.
In this CME series, nursing leaders of the International Myeloma Foundation's Nurse Leadership Board (NLB) will present timely information surrounding the disparities in clinical presentation and access to care that disproportionately affect African American patients, as well as highlight best practices for nurses aimed at eliminating disparities and achieving equity in healthcare.
Multiple myeloma care is rapidly evolving with new agents and combinations, new testing, and risk-adapted treatment strategies. Four highly experienced nurses will share their expertise during this 1.5 CNE symposium (3 sessions of 0.5 CNE) while using real-life patient case scenarios to focus on symptom management, infection control, and nursing implications.
Presented by Rafat Abonour, MD; Thomas Martin, MD; Joseph Mikhael, MD, MEd, FRCPC; these courses discuss the Role of Proteasome Inhibition in Multiple Myeloma.
Presented by Medscape Oncology and moderated by Dr. Brian G.M. Durie the sections of this activity include: Continuous Treatment of Transplant-Ineligible Patients, After Transplant: The Role of Maintenance With or Without Prior Consolidation, Selecting Myeloma Maintenance Therapy for High-Risk Patients, Multiple Myeloma Maintenance Therapy: How Long Do I Treat?, and Management of Adverse Events Associated With Maintenance Therapy.
